Agenus | AGEN - Sales Revenues


Agenus reported $33.7M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Agenus USD 33.7M 500K Mar/2026
Amgen USD 10.1B 1.48B Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Celldex Therapeutics USD 22K 7K Jun/2026
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 22.97B 3.17B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.67B 400M Jun/2026
Intrexon USD 717K 511K Jun/2024
J&J USD 25.4B 89M Sep/2026
Jiangsu Hengrui CNY 8.63B 490M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck EUR 5.43B 300M Jun/2026
Merck USD 16.6B 310M Jun/2026
Northwest Biotherapeutics USD 494K 294K Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 15.03B 530M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 150.32M 11.25M Jun/2026